Back to Search
Start Over
Recombinant MUC 1 vaccinia virus: a potential vector for immunotherapy of breast cancer.
- Source :
-
Cellular and molecular biology (Noisy-le-Grand, France) [Cell Mol Biol (Noisy-le-grand)] 1994; Vol. 40 Suppl 1, pp. 49-59. - Publication Year :
- 1994
-
Abstract
- Breast cancer is considered as the major cause of mortality by cancer for women. Even if chemotherapy, radiotherapy and surgery have improved the life expectancy of patients bearing tumours, breast cancer is responsible for the death of 42,000 women per year in USA and 25,000 women in France. In this context, cancer vaccines may add an attractive alternative therapeutic strategy to the current existing treatments. We describe here the construction of recombinant vaccinia viruses co-expressing a tumour associated antigen (MUC 1) and an "adjuvant" cytokine, which have potential applications in the active immunotherapy of breast cancer. Indeed, recombinant vaccinia viruses have been extensively used during the past decade to induce a protective response against a whole variety of pathogens, and has proven to be of great value in the elicitation of a cellular immune response leading to the rejection of tumour grafts in mouse models.
- Subjects :
- Animals
Base Sequence
Breast Neoplasms immunology
Combined Modality Therapy
Cytokines genetics
DNA, Complementary genetics
Female
Genetic Vectors
Humans
Mice
Molecular Sequence Data
Mucin-1
Recombinant Proteins genetics
Recombinant Proteins immunology
Repetitive Sequences, Nucleic Acid
Antigens, Neoplasm genetics
Breast Neoplasms therapy
Immunotherapy methods
Membrane Glycoproteins genetics
Membrane Glycoproteins immunology
Mucins genetics
Mucins immunology
Vaccinia virus genetics
Vaccinia virus immunology
Subjects
Details
- Language :
- English
- ISSN :
- 0145-5680
- Volume :
- 40 Suppl 1
- Database :
- MEDLINE
- Journal :
- Cellular and molecular biology (Noisy-le-Grand, France)
- Publication Type :
- Academic Journal
- Accession number :
- 7950862